Annovis Bio (ANVS) announced it was granted the U.S. patent covering methods for the treatment and prevention of acute brain ...

Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative ...

Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer's and Parkinson's. The company is developing innovative therapies that ...

In recent trading, Annovis Bio Inc (ANVS) stock price has shown some volatility, fluctuating -0.59% over the last five trades and -13.2 ...

Annovis Bio (NYSEMKT:ANVS) just reported results for the first quarter of 2024. Annovis Bio reported earnings per share of -72 cents. This was above the analyst estimate for EPS of -80 cents.

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Annovis Bio (ANVS – Research Report), retaining the price target of ...

Annovis Bio (ANVS) announced that the FDA has accepted an updated protocol for the pivotal Phase 3 Alzheimer’s Disease study, which is slated ...

Shares of Annovis Bio, Inc. (NYSE:ANVS – Get Free Report) have received an average rating of “Buy” from the seven analysts that are covering the company, MarketBeat reports.One equities ...

Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...

MALVERN, Pa., Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, is pleased ...